APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Peptic Ulcer Drugs

Anti-peptic Ulcre drug is one of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Anti-peptic Ulcre drug is one of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.

Selected research

Market Outlook & Growth Opportunities

Global Anti-Peptic Ulcer Drugs Market Outlook and Growth Opportunities 2026

21 December 2025198 pages

Choose your research edition.

Industry ResearchAnti-Peptic Ulcer Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Peptic Ulcer Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Anti-Peptic Ulcer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Peptic Ulcer Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Peptic Ulcer Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Anti-peptic Ulcre drug is one of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.

Global Anti-Peptic Ulcer Drugs key players include AstraZeneca, Ask-pharm, Takeda, Yangtze River Pharm, Shandong Luoxin, etc. Global top five players hold a share about 50%.

In terms of product, the segment includes Proton Pump Inhibitors (PPIs), Potassium-Competitive Acid Blockers (P-CAB), Antacids, H2 Antagonists, Ulcer Protective Drugs. And in terms of application, the application includes Gastritis, Gastric Ulcers, Duodenal Ulcers, Gastroesophageal Reflux Disease (GERD).

Read the full market overview

This report provides an overview of the global Anti-Peptic Ulcer Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-Peptic Ulcer Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-Peptic Ulcer Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Anti-Peptic Ulcer Drugs market.

Anti-Peptic Ulcer Drugs Segment by Company

AstraZeneca

Ask-pharm

Takeda

Yangtze River Pharm

Shandong Luoxin

Huadong Medicine

Changzhou Siyao

Beijing Yuekang

Guangdong Dahua

Xian Janssen

Anti-Peptic Ulcer Drugs Segment by Type

Proton Pump Inhibitors (PPIs)

Potassium-Competitive Acid Blockers (P-CAB)

Antacids

H2 Antagonists

Ulcer Protective Drugs

Anti-Peptic Ulcer Drugs Segment by Application

Gastritis

Gastric Ulcers

Duodenal Ulcers

Gastroesophageal Reflux Disease (GERD)

Anti-Peptic Ulcer Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anti-Peptic Ulcer Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Anti-Peptic Ulcer Drugs key companies, revenue, market share, and recent developments.

3. To split the Anti-Peptic Ulcer Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Anti-Peptic Ulcer Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-Peptic Ulcer Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-Peptic Ulcer Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Peptic Ulcer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Peptic Ulcer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Peptic Ulcer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-Peptic Ulcer Drugs industry.

Chapter 3: Detailed analysis of Anti-Peptic Ulcer Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Anti-Peptic Ulcer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Anti-Peptic Ulcer Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-Peptic Ulcer Drugs Industry Trends Table 2. Anti-Peptic Ulcer Drugs Industry Drivers Table 3. Anti-Peptic Ulcer Drugs Industry Opportunities and Challenges Table 4. Anti-Peptic Ulcer Drugs Industry Restraints Table 5. Global Anti-Peptic Ulcer Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-Peptic Ulcer Drugs Revenue Share by Company (2021-2026) Table 7. Global Anti-Peptic Ulcer Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Anti-Peptic Ulcer Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Anti-Peptic Ulcer Drugs Company, Product Type & Application Table 10. Global Anti-Peptic Ulcer Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Anti-Peptic Ulcer Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Proton Pump Inhibitors (PPIs) Table 15. Significant Companies of Potassium-Competitive Acid Blockers (P-CAB) Table 16. Significant Companies of Antacids Table 17. Significant Companies of H2 Antagonists Table 18. Significant Companies of Ulcer Protective Drugs Table 19. Global Anti-Peptic Ulcer Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Anti-Peptic Ulcer Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Anti-Peptic Ulcer Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Anti-Peptic Ulcer Drugs Sales Value Share by Type (2021-2026) Table 23. Global Anti-Peptic Ulcer Drugs Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Gastritis Table 25. Significant Companies of Gastric Ulcers Table 26. Significant Companies of Duodenal Ulcers Table 27. Significant Companies of Gastroesophageal Reflux Disease (GERD) Table 28. Global Anti-Peptic Ulcer Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Anti-Peptic Ulcer Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Anti-Peptic Ulcer Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Anti-Peptic Ulcer Drugs Sales Value Share by Application (2021-2026) Table 32. Global Anti-Peptic Ulcer Drugs Sales Value Share by Application (2027-2032) Table 33. Global Anti-Peptic Ulcer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Anti-Peptic Ulcer Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Anti-Peptic Ulcer Drugs Sales Value Share by Region (2021-2026) Table 36. Global Anti-Peptic Ulcer Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Anti-Peptic Ulcer Drugs Sales Value Share by Region (2027-2032) Table 38. Global Anti-Peptic Ulcer Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Anti-Peptic Ulcer Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Anti-Peptic Ulcer Drugs Sales Value Market Share by Country (2021-2026) Table 41. Global Anti-Peptic Ulcer Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Anti-Peptic Ulcer Drugs Sales Value Market Share by Country (2027-2032) Table 43. AstraZeneca Company Information Table 44. AstraZeneca Business Overview Table 45. AstraZeneca Anti-Peptic Ulcer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. AstraZeneca Anti-Peptic Ulcer Drugs Product Portfolio Table 47. AstraZeneca Recent Development Table 48. Ask-pharm Company Information Table 49. Ask-pharm Business Overview Table 50. Ask-pharm Anti-Peptic Ulcer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Ask-pharm Anti-Peptic Ulcer Drugs Product Portfolio Table 52. Ask-pharm Recent Development Table 53. Takeda Company Information Table 54. Takeda Business Overview Table 55. Takeda Anti-Peptic Ulcer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Takeda Anti-Peptic Ulcer Drugs Product Portfolio Table 57. Takeda Recent Development Table 58. Yangtze River Pharm Company Information Table 59. Yangtze River Pharm Business Overview Table 60. Yangtze River Pharm Anti-Peptic Ulcer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Yangtze River Pharm Anti-Peptic Ulcer Drugs Product Portfolio Table 62. Yangtze River Pharm Recent Development Table 63. Shandong Luoxin Company Information Table 64. Shandong Luoxin Business Overview Table 65. Shandong Luoxin Anti-Peptic Ulcer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Shandong Luoxin Anti-Peptic Ulcer Drugs Product Portfolio Table 67. Shandong Luoxin Recent Development Table 68. Huadong Medicine Company Information Table 69. Huadong Medicine Business Overview Table 70. Huadong Medicine Anti-Peptic Ulcer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Huadong Medicine Anti-Peptic Ulcer Drugs Product Portfolio Table 72. Huadong Medicine Recent Development Table 73. Changzhou Siyao Company Information Table 74. Changzhou Siyao Business Overview Table 75. Changzhou Siyao Anti-Peptic Ulcer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Changzhou Siyao Anti-Peptic Ulcer Drugs Product Portfolio Table 77. Changzhou Siyao Recent Development Table 78. Beijing Yuekang Company Information Table 79. Beijing Yuekang Business Overview Table 80. Beijing Yuekang Anti-Peptic Ulcer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Beijing Yuekang Anti-Peptic Ulcer Drugs Product Portfolio Table 82. Beijing Yuekang Recent Development Table 83. Guangdong Dahua Company Information Table 84. Guangdong Dahua Business Overview Table 85. Guangdong Dahua Anti-Peptic Ulcer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Guangdong Dahua Anti-Peptic Ulcer Drugs Product Portfolio Table 87. Guangdong Dahua Recent Development Table 88. Xian Janssen Company Information Table 89. Xian Janssen Business Overview Table 90. Xian Janssen Anti-Peptic Ulcer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Xian Janssen Anti-Peptic Ulcer Drugs Product Portfolio Table 92. Xian Janssen Recent Development Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Anti-Peptic Ulcer Drugs Product Image Figure 2. Global Anti-Peptic Ulcer Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Peptic Ulcer Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-Peptic Ulcer Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Proton Pump Inhibitors (PPIs) Image Figure 8. Potassium-Competitive Acid Blockers (P-CAB) Image Figure 9. Antacids Image Figure 10. H2 Antagonists Image Figure 11. Ulcer Protective Drugs Image Figure 12. Global Anti-Peptic Ulcer Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Anti-Peptic Ulcer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Anti-Peptic Ulcer Drugs Sales Value Share by Type (2021-2032) Figure 15. Gastritis Image Figure 16. Gastric Ulcers Image Figure 17. Duodenal Ulcers Image Figure 18. Gastroesophageal Reflux Disease (GERD) Image Figure 19. Global Anti-Peptic Ulcer Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Anti-Peptic Ulcer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Anti-Peptic Ulcer Drugs Sales Value Share by Application (2021-2032) Figure 22. Global Anti-Peptic Ulcer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Anti-Peptic Ulcer Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Anti-Peptic Ulcer Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. North America Anti-Peptic Ulcer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Anti-Peptic Ulcer Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Anti-Peptic Ulcer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Anti-Peptic Ulcer Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Anti-Peptic Ulcer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Anti-Peptic Ulcer Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. South America Anti-Peptic Ulcer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Anti-Peptic Ulcer Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Anti-Peptic Ulcer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Proton Pump Inhibitors (PPIs)
  • Potassium-Competitive Acid Blockers (P-CAB)
  • Antacids
  • H2 Antagonists
  • Ulcer Protective Drugs
Applications
  • Gastritis
  • Gastric Ulcers
  • Duodenal Ulcers
  • Gastroesophageal Reflux Disease (GERD)
Companies covered
  • AstraZeneca
  • Ask-pharm
  • Takeda
  • Yangtze River Pharm
  • Shandong Luoxin
  • Huadong Medicine
  • Changzhou Siyao
  • Beijing Yuekang
  • Guangdong Dahua
  • Xian Janssen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anti-Peptic Ulcer Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anti-Peptic Ulcer Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Anti-Peptic Ulcer Drugs Market Dynamics
  1. 2.1 Anti-Peptic Ulcer Drugs Industry Trends
  2. 2.2 Anti-Peptic Ulcer Drugs Industry Drivers
  3. 2.3 Anti-Peptic Ulcer Drugs Industry Opportunities and Challenges
  4. 2.4 Anti-Peptic Ulcer Drugs Industry Restraints
3 Anti-Peptic Ulcer Drugs Market by Company
  1. 3.1 Global Anti-Peptic Ulcer Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Anti-Peptic Ulcer Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Anti-Peptic Ulcer Drugs Company Ranking (2024-2026)
  4. 3.4 Global Anti-Peptic Ulcer Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Anti-Peptic Ulcer Drugs Company Product Type and Application
  6. 3.6 Global Anti-Peptic Ulcer Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Anti-Peptic Ulcer Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Anti-Peptic Ulcer Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Anti-Peptic Ulcer Drugs Market by Type
  1. 4.1 Anti-Peptic Ulcer Drugs Type Introduction
  2. 4.1.1 Proton Pump Inhibitors (PPIs)
  3. 4.1.2 Potassium-Competitive Acid Blockers (P-CAB)
  4. 4.1.3 Antacids
  5. 4.1.4 H2 Antagonists
  6. 4.1.5 Ulcer Protective Drugs
  7. 4.2 Global Anti-Peptic Ulcer Drugs Sales Value by Type
  8. 4.2.1 Global Anti-Peptic Ulcer Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Anti-Peptic Ulcer Drugs Sales Value by Type (2021-2032)
  10. 4.2.3 Global Anti-Peptic Ulcer Drugs Sales Value Share by Type (2021-2032)
5 Anti-Peptic Ulcer Drugs Market by Application
  1. 5.1 Anti-Peptic Ulcer Drugs Application Introduction
  2. 5.1.1 Gastritis
  3. 5.1.2 Gastric Ulcers
  4. 5.1.3 Duodenal Ulcers
  5. 5.1.4 Gastroesophageal Reflux Disease (GERD)
  6. 5.2 Global Anti-Peptic Ulcer Drugs Sales Value by Application
  7. 5.2.1 Global Anti-Peptic Ulcer Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Anti-Peptic Ulcer Drugs Sales Value by Application (2021-2032)
  9. 5.2.3 Global Anti-Peptic Ulcer Drugs Sales Value Share by Application (2021-2032)
6 Anti-Peptic Ulcer Drugs Regional Value Analysis
  1. 6.1 Global Anti-Peptic Ulcer Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-Peptic Ulcer Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Anti-Peptic Ulcer Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Anti-Peptic Ulcer Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anti-Peptic Ulcer Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Anti-Peptic Ulcer Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Anti-Peptic Ulcer Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Anti-Peptic Ulcer Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Anti-Peptic Ulcer Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Anti-Peptic Ulcer Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Anti-Peptic Ulcer Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Anti-Peptic Ulcer Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Anti-Peptic Ulcer Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Anti-Peptic Ulcer Drugs Sales Value Share by Country, 2025 VS 2032
7 Anti-Peptic Ulcer Drugs Country-level Value Analysis
  1. 7.1 Global Anti-Peptic Ulcer Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-Peptic Ulcer Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Anti-Peptic Ulcer Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Anti-Peptic Ulcer Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Anti-Peptic Ulcer Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Anti-Peptic Ulcer Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Anti-Peptic Ulcer Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca
  2. 8.1.1 AstraZeneca Company Information
  3. 8.1.2 AstraZeneca Business Overview
  4. 8.1.3 AstraZeneca Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca Anti-Peptic Ulcer Drugs Product Portfolio
  6. 8.1.5 AstraZeneca Recent Developments
  7. 8.2 Ask-pharm
  8. 8.2.1 Ask-pharm Company Information
  9. 8.2.2 Ask-pharm Business Overview
  10. 8.2.3 Ask-pharm Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ask-pharm Anti-Peptic Ulcer Drugs Product Portfolio
  12. 8.2.5 Ask-pharm Recent Developments
  13. 8.3 Takeda
  14. 8.3.1 Takeda Company Information
  15. 8.3.2 Takeda Business Overview
  16. 8.3.3 Takeda Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Takeda Anti-Peptic Ulcer Drugs Product Portfolio
  18. 8.3.5 Takeda Recent Developments
  19. 8.4 Yangtze River Pharm
  20. 8.4.1 Yangtze River Pharm Company Information
  21. 8.4.2 Yangtze River Pharm Business Overview
  22. 8.4.3 Yangtze River Pharm Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Yangtze River Pharm Anti-Peptic Ulcer Drugs Product Portfolio
  24. 8.4.5 Yangtze River Pharm Recent Developments
  25. 8.5 Shandong Luoxin
  26. 8.5.1 Shandong Luoxin Company Information
  27. 8.5.2 Shandong Luoxin Business Overview
  28. 8.5.3 Shandong Luoxin Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Shandong Luoxin Anti-Peptic Ulcer Drugs Product Portfolio
  30. 8.5.5 Shandong Luoxin Recent Developments
  31. 8.6 Huadong Medicine
  32. 8.6.1 Huadong Medicine Company Information
  33. 8.6.2 Huadong Medicine Business Overview
  34. 8.6.3 Huadong Medicine Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Huadong Medicine Anti-Peptic Ulcer Drugs Product Portfolio
  36. 8.6.5 Huadong Medicine Recent Developments
  37. 8.7 Changzhou Siyao
  38. 8.7.1 Changzhou Siyao Company Information
  39. 8.7.2 Changzhou Siyao Business Overview
  40. 8.7.3 Changzhou Siyao Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Changzhou Siyao Anti-Peptic Ulcer Drugs Product Portfolio
  42. 8.7.5 Changzhou Siyao Recent Developments
  43. 8.8 Beijing Yuekang
  44. 8.8.1 Beijing Yuekang Company Information
  45. 8.8.2 Beijing Yuekang Business Overview
  46. 8.8.3 Beijing Yuekang Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Beijing Yuekang Anti-Peptic Ulcer Drugs Product Portfolio
  48. 8.8.5 Beijing Yuekang Recent Developments
  49. 8.9 Guangdong Dahua
  50. 8.9.1 Guangdong Dahua Company Information
  51. 8.9.2 Guangdong Dahua Business Overview
  52. 8.9.3 Guangdong Dahua Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Guangdong Dahua Anti-Peptic Ulcer Drugs Product Portfolio
  54. 8.9.5 Guangdong Dahua Recent Developments
  55. 8.10 Xian Janssen
  56. 8.10.1 Xian Janssen Company Information
  57. 8.10.2 Xian Janssen Business Overview
  58. 8.10.3 Xian Janssen Anti-Peptic Ulcer Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Xian Janssen Anti-Peptic Ulcer Drugs Product Portfolio
  60. 8.10.5 Xian Janssen Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst